Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.

Soo RA, Kawaguchi T, Loh M, Ou SH, Shieh MP, Cho BC, Mok TS, Soong R.

Future Oncol. 2012 Apr;8(4):451-62. doi: 10.2217/fon.12.25. Review.

PMID:
22515448
2.

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, Wong J, McNeil E, Bishop JF.

Ann Oncol. 2003 Mar;14(3):449-54.

3.
4.

The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

Chang AY.

Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. doi: 10.1517/13543784.17.3.401 . Review. Erratum in: Expert Opin Investig Drugs. 2008 May;17(5):825.

PMID:
18321238
5.

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.

Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC.

J Clin Pharm Ther. 2012 Jun;37(3):266-75. doi: 10.1111/j.1365-2710.2011.01289.x. Epub 2011 Sep 26. Review.

PMID:
21950464
6.

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C.

Lung Cancer. 2012 Aug;77(2):339-45. doi: 10.1016/j.lungcan.2012.03.012. Epub 2012 Apr 10.

PMID:
22494567
7.

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.

Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG.

Clin Lung Cancer. 2006 Mar;7(5):326-31.

PMID:
16640804
8.

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Jiang H.

Jpn J Clin Oncol. 2009 Mar;39(3):137-50. doi: 10.1093/jjco/hyn139. Epub 2008 Dec 16. Review.

9.
10.

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC.

Cancer. 2006 Oct 15;107(8):1873-82.

11.

Emerging ethnic differences in lung cancer therapy.

Sekine I, Yamamoto N, Nishio K, Saijo N.

Br J Cancer. 2008 Dec 2;99(11):1757-62. doi: 10.1038/sj.bjc.6604721. Epub 2008 Nov 4. Review.

12.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX.

J Exp Clin Cancer Res. 2010 Sep 15;29:126. doi: 10.1186/1756-9966-29-126.

13.

The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.

Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL.

Eur J Pharmacol. 2007 Sep 10;570(1-3):175-81. Epub 2007 Jun 5.

PMID:
17597605
14.

Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.

Biaoxue R, Shuanying Y, Wei L, Wei Z, Zongjuan M.

Curr Med Res Opin. 2012 Oct;28(10):1699-708. doi: 10.1185/03007995.2012.728525. Epub 2012 Oct 2. Review.

PMID:
22978775
15.

Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.

Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM.

Lung Cancer. 2006 Nov;54(2):193-9. Epub 2006 Sep 22.

PMID:
16996166
16.

Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK.

Nimako K, Gunapala R, Popat S, O'Brien ME.

Eur J Cancer Care (Engl). 2013 Jan;22(1):79-87. doi: 10.1111/j.1365-2354.2012.01373.x. Epub 2012 Jun 28.

PMID:
22738286
17.

Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?

Loh M, Chua D, Yao Y, Soo RA, Garrett K, Zeps N, Platell C, Minamoto T, Kawakami K, Iacopetta B, Soong R.

Pharmacogenomics J. 2013 Oct;13(5):423-9. doi: 10.1038/tpj.2012.26. Epub 2012 Jun 26.

PMID:
22733238
18.

Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives.

Johnson L, Barnard JJ, Rodriguez L, Smith EC, Swerdloff RS, Wang XH, Wang C.

J Androl. 1998 May-Jun;19(3):348-57.

19.

Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.

Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK.

Arch Intern Med. 2002 Sep 23;162(17):1985-93.

PMID:
12230422
20.

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.

Lee DH, Kim SW, Suh C, Han YH, Lee JS.

Cancer Chemother Pharmacol. 2011 Jan;67(1):35-9. doi: 10.1007/s00280-010-1280-6. Epub 2010 Feb 25.

PMID:
20182725
Items per page

Supplemental Content

Write to the Help Desk